Tag

Type 2 Diabetes

All articles tagged with #type 2 diabetes

Fat quality matters: olive oil linked to lower type 2 diabetes risk, review finds
health17 days ago

Fat quality matters: olive oil linked to lower type 2 diabetes risk, review finds

A new review in Trends in Endocrinology & Metabolism suggests fat quality—not total fat intake—may affect type 2 diabetes risk. Palmitic acid, a saturated fat common in meats, dairy and palm oil, can impair insulin action and promote inflammation, while oleic acid found in olive oil may help preserve insulin sensitivity. Diets high in unsaturated fats and patterns like the Mediterranean diet are linked to lower diabetes risk, though much evidence comes from lab and observational studies; more human trials are needed. Practical guidance: replace some saturated fats with heart-healthy fats (olive oil, nuts, seeds) and maintain a healthy lifestyle to reduce diabetes risk.

Semaglutide drugs may fortify bones in type 2 diabetes, new study suggests
health21 days ago

Semaglutide drugs may fortify bones in type 2 diabetes, new study suggests

A study of about 59,000 adults with type 2 diabetes found semaglutide (the active ingredient in Ozempic/Wegovy) users had roughly 15% fewer bone fractures than peers on other weight‑loss meds (794 fractures among 26,324 semaglutide users vs 1,045 among 33,555 non‑semaglutide users), despite greater weight loss. The findings, presented at ENDO 2026, suggest a potential bone‑health benefit from semaglutide and underscore monitoring of bone health in weight‑loss therapies for older adults.

Cohabitation Accelerates Microbiome Sharing, Tied to Diabetes Risk
science25 days ago

Cohabitation Accelerates Microbiome Sharing, Tied to Diabetes Risk

A study of 430 people in 207 households across Italy and Fiji shows that living under the same roof drives large-scale transfer of gut and oral bacterial strains, far exceeding genetic relatedness. Cohabitants share ~19% of gut and ~26% of oral strains, while romantically involved partners share about 44% of oral strains. Non-cohabiting individuals share markedly fewer strains. Importantly, the most transmissible gut bacteria correlate with biomarkers of Type 2 diabetes and poor cardiometabolic health, and certain oral strains linked to colorectal cancer. These findings could inform more effective probiotic and fecal microbiota transplant therapies by leveraging natural transmission traits.

Genetic clues link higher caffeine levels to lower body fat and diabetes risk
health1 month ago

Genetic clues link higher caffeine levels to lower body fat and diabetes risk

A 2023 Mendelian randomization study using data from about 10,000 people found that genetically higher plasma caffeine concentrations are associated with lower BMI and fat mass, and a reduced risk of type 2 diabetes (about half of the effect mediated by BMI). There was no clear link to cardiovascular diseases. The authors note caffeine metabolism genes CYP1A2 and AHR influence caffeine levels, and suggest caffeine may boost thermogenesis and fat oxidation; however causal relationships aren’t proven and randomized trials are needed to confirm whether non-caloric caffeinated beverages could help reduce obesity or diabetes risk.

Olive-Oil Fat Protects Against Diabetes While Palm Fat Hurts Insulin, Study Says
health1 month ago

Olive-Oil Fat Protects Against Diabetes While Palm Fat Hurts Insulin, Study Says

A new review from the University of Barcelona finds that palmitic acid (a saturated fat) impairs insulin sensitivity and promotes inflammation, while oleic acid (a monounsaturated fat common in olive oil) improves insulin signaling and fat handling, suggesting fat quality matters more than total fat intake and helping explain the diabetes-protective associations of Mediterranean diets; more research is needed to resolve conflicting epidemiological results and consider fat source and processing.

Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission
healthcare2 months ago

Lilly’s Foundayo earns non-inferiority and cardiometabolic gains in ACHIEVE-4, fueling FDA submission

In ACHIEVE-4, the largest/longest Phase 3 trial of Foundayo (orforglipron) vs insulin glargine in adults with type 2 diabetes at high CV risk, Foundayo met non-inferiority for MACE-4 and showed 16% lower risk for MACE-4 and 23% lower risk for MACE-3; a pre-planned analysis also showed 57% lower risk of all-cause death. The study (2,700+ participants across 15 countries) demonstrated sustained A1C and body-weight improvements through 104 weeks. Lilly intends to submit Foundayo to the FDA for type 2 diabetes by end of Q2.

Blood Type B Linked to Modest Increase in Type 2 Diabetes Risk, Study Finds
health3 months ago

Blood Type B Linked to Modest Increase in Type 2 Diabetes Risk, Study Finds

A 2024 umbrella review of 51 meta-analyses (covering about 270 blood-group–health links) finds only one robust association: blood type B has about a 28% higher risk of type 2 diabetes than non-B types; the effect is modest and far smaller than risk factors like diet, obesity, or inactivity, and researchers call for more rigorous work and study of potential mechanisms such as the gut microbiome; published in BMC Medicine.

Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial
health3 months ago

Lilly's retatrutide delivers strong A1C drops and meaningful weight loss in first Phase 3 Type 2 diabetes trial

Lilly reports positive topline results from TRANSCEND-T2D-1, a Phase 3 trial of retatrutide, a once-weekly triple hormone receptor agonist (GIP, GLP-1, glucagon), showing up to a 2.0% reduction in A1C and about 17% body-weight loss at 40 weeks versus placebo, with dose-dependent effects and continued weight loss through the treatment period. The most common side effects were gastrointestinal (nausea, diarrhea, vomiting) largely during dose escalation, with some dysesthesia but generally manageable. Results met primary and key secondary endpoints and will be detailed at the ADA Scientific Sessions in June; Lilly plans to publish additional data from the retatrutide program over the next year.

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial
business3 months ago

Lilly's Triple-Hormone Drug Retatrutide Delivers Promising Diabetes, Weight Loss in Phase 3 Trial

Eli Lilly's next‑generation obesity drug retatrutide showed strong Phase 3 results in Type 2 diabetes, lowering A1C by about 1.7%–2% at 40 weeks and achieving roughly 16.8% weight loss at the highest dose among patients who stayed on treatment, with a tolerable safety profile. The company has not filed for approval yet and plans additional Phase 3 trials, pursuing retatrutide as a key pillar of its obesity/diabetes portfolio alongside Zepbound and orforglipron, as Novo Nordisk races to catch up.

GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans
health4 months ago

GLP-1 Medications Tied to Broad Decrease in Addiction Risk Among Veterans

A VA-led cohort study of 606,434 U.S. veterans with type 2 diabetes found that GLP-1 medicines (including Ozempic, Wegovy, Mounjaro, and Zepbound) are associated with a lower risk of developing substance use disorders across alcohol, opioids, nicotine, cocaine, cannabis and other substances—and with fewer hospitalizations, overdoses, and deaths among veterans who already have an addiction. The study also notes a 25% reduction in suicidal ideation. As observational research, it cannot prove causation, and results may reflect greater health engagement; randomized trials are underway, and GLP-1s are not yet approved as addiction treatments.

Sugary Drinks Linked to 340,000 Deaths Worldwide in 2020
health4 months ago

Sugary Drinks Linked to 340,000 Deaths Worldwide in 2020

A Nature Medicine analysis tying sugar-sweetened beverages to 340,000 deaths in 2020 from heart disease and type 2 diabetes finds 2.2 million new diabetes and 1.2 million heart disease cases linked to SSBs that year. The burden is greatest in Latin America and the Caribbean and sub-Saharan Africa, with younger urban men most affected. Mechanisms include rapid liquid sugar absorption causing glucose spikes, insulin resistance, visceral fat, and inflammation. Experts recommend limiting SSBs and replacing them with water or non-caloric drinks, and suggest less than one serving per week for many people; note that the study is observational, showing association, not causation.

Global Study Reframes Type 2 Diabetes as Tissue-Driven and Population-Specific
science5 months ago

Global Study Reframes Type 2 Diabetes as Tissue-Driven and Population-Specific

A large international genetic study analyzing data from over 2.5 million people across seven tissues finds that many Type 2 diabetes drivers act outside the bloodstream. Only about 18% of causal genes in key diabetes tissues are detectable in blood, while 85% of signals in diabetes-relevant tissues are missed by blood-based analyses. The study links 676 genes to causal effects, including 335 genes and 46 proteins that influence risk, with some associations consistent across ancestry groups and others emerging only in historically underrepresented populations. Published in Nature Metabolism, the work underscores the importance of tissue context and population diversity for improving prevention and treatment strategies.